Related Experiment Video
Updated: Sep 30, 2026
Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
Published on: October 30, 2013
[Intraprostatic BCG vaccine in patients with prostatic cancer. Expression of interferon gamma and interleukin 4 (a
P Rivera1, J Inostroza, F Treulén
1Servicio de Urología, Hospital Regional Temuco, Unidad de Urología, Departamento de Especialidades, Departamento de Ciencias Básicas, Universidad de la Frontera de Temuco.
Unlabelled:
The BCG treatment in the superficial bladder cancer is utilized since 1976. There are some animal experiences with BCG intraprostatic in dogs with prostatic cancer.
Goal:
determine if insitu BCG vaccine increase the prostatic immunity in patients with prostatic cancer.
Material And Method:
Three patients with D stage prostatic cancer where injected with 0.3-0.5 mg of BCG vaccine in the prostate. An histological picture where made in the some place before and after the injection. A RT-PCR study was made for gamma Interferon and Interleukin-4.
Results:
In two patients we observed gamma interferon expression (67%) respect the control, this produce an increase of the cytotoxic T lymphocytes, natural killer cells and macrophagos, that have antitumoral action. One patient increased the interleukin-4 that means production of T helper lymphocytes and B lymphocytes. There wasn't complications.
Conclusions:
The BCG vaccine injected in prostatic tissue of patients with prostatic cancer, produces an increase of cytotoxic T lymphocytes and natural killer cells, with antitumoral action.
Related Concept Videos
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
01:27Tumor Immunotherapy